TScan Therapeutics (TCRX) Earnings Date & Reports

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

TCRX is expected to report earnings to rise 9.43% to -25 cents per share on November 11

TScan Therapeutics TCRX Stock Earnings Reports

Q3'26

Est.

$-0.25

Q2'26

Beat

by $0.03

Q1'26

Missed

by $0.04

Q4'25

Beat

by $0.09

Q3'25

Beat

by $0.06

The last earnings report on August 12 showed earnings per share of -23 cents, beating the estimate of -25 cents. With 68.73K shares outstanding, the current market capitalization sits at 23.04M.

View a ticker or compare two or three

TCRX

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for TCRX